瘤微环境响应纳米集群用于时间解决的高热内化疗/热疗对结直肠外转移的治疗
Qiping Wu1,2, Nanzhou Wang3,4, Shiwen Wang2,5
1Institute of Biomedical Engineering, College of Life Sciences, Qingdao University, Qingdao 266071, China.
ACS applied bio materials
|August 4, 2025
概括
一个新的纳米集群系统 (MoNs@MyC) 增强了腹膜转移的高热内皮质化疗 (HIPEC). 这种双响应治疗改善了药物保留,协同化疗-高温症,并降低了毒性,提供了一个有前途的精确疗法.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 药物输送系统 药物输送系统
背景情况:
- 来自胃肠道癌的腹转移 (PM) 由于其扩散性和药物透性差, presents显著的治疗挑战.
- 目前的高热性腹膜内化学疗法 (HIPEC) 提供了生存益处,但受到系统毒性和癌细胞耐热性的限制.
研究的目的:
- 开发一种瘤微环境响应型纳米集群系统 (MoNs@MyC),用于增强腹膜转移的HIPEC治疗.
- 为了增强局部药物保留,与二次高温症协同化疗,并减少全身毒性.
主要方法:
- 开发超小的单分散纳米集群 (MoN) 装载着米托菌素C (MyC).
- 在酸性瘤环境中,MoNs@MyC自组装成微型颗粒,增强HIPEC期间的药物保留.
- 使用光热转换用于二次高温症,并评估健康组织中氧化损伤的缓解.
主要成果:
- 与传统的HIPEC相比,MoNs@MyC在腹膜转移小鼠模型中显示了增强的局部药物保留和优越的瘤控制.
- 该系统有效地将化疗与光热过热症结合起来,克服了癌细胞的热阻力.
- 在健康组织中,MoNs@MyC可选择性地减少了米托米辛C诱导的氧化损伤,并刺激了抗瘤免疫力.
结论:
- 双响应的MoNs@MyC系统代表了精确腹转移疗法的转型策略.
- 这种方法提高了局部治疗的疗效,同时提高了系统安全性,弥合了当前治疗方法的关键差距.
- 可扩展的合成和具有成本效益的设计支持其在腹膜转移中潜在的临床转化.
更多相关视频
07:47Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
Published on: December 13, 2015
9.1K
10:23Author Spotlight: Computing the Effects of a Local Radiofrequency Hyperthermia Intervention on Tumor Biomechanics
Published on: December 1, 2023
542
相关概念视频
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660